Platform Collaboration Alaunos is prioritizing its hunTR TCR discovery platform, creating a clear entry point for strategic collaborations or licensing deals with pharma and biotech partners seeking TCR discovery capabilities for solid tumors.

Financing Leverage With recent funding activity and a clinical-stage profile, Alaunos is positioned to pursue milestone based partnerships, co development, or out licensing of its platform and pipeline to reduce R&D risk for both parties.

Neoantigen Focus Their neoantigen targeting TCR-T platform differentiates them, making them attractive for collaborations with oncology programs seeking next generation cell therapies and neoantigen libraries.

Ecosystem Access Located in Houston near the world's largest medical center, enabling easier access to clinical trial sites, KOLs, and hospital networks for joint research, patient recruitment, and clinical partnerships.

Scale Enablement As a small team, Alaunos may benefit from CRO and CMO manufacturing, regulatory, and data infrastructure services. Target BD outreach with partners offering end to end discovery through manufacturing capabilities.